Abstract
INTRODUCTION
Tobacco smoking is a preventable cause of disease and death worldwide. Shisha has become a popular method of smoking tobacco. In Qatar, the prevalence of smoking in 2019 was 25.2%, of which 20.9% was smoking shisha. Shisha smoking is thought to have a harmful effect on the cardiovascular system. The main objective of this study was to understand the relationship between shisha smoking and cardiovascular disease risks.
METHODS
All data were obtained from the Qatar Biobank (QBB). The study population consisted of 1045 individuals, which included cases defined as participants who had a history of angina, heart attack and/or stroke and their matched healthy controls for age and gender. The measurement of both the exposure and the outcome was done through the survey provided by QBB. A conditional logistic regression model was used to assess the association between smoking and cardiovascular disease (CVD), and adjusted odds ratio (AOR) and 95% confidence intervals (CI) were calculated after adjusting for covariates.
RESULTS
After adjusting for hypertension diagnosis, diabetes diagnosis, dyslipidemia diagnosis, abdominal obesity, and sedentary lifestyle, exclusive shisha smokers had 1.65 times higher odds of reporting cardiovascular disease diagnoses compared to non-smokers (95% CI: 0.71–1.91). Dual shisha and cigarette smokers also had 1.47 times higher odds of reporting cardiovascular disease diagnoses compared to non-smokers (95% CI: 0.88–2.45). CVD cases had a younger median age of initial shisha smoking compared to controls (20 years vs 25 years, p=0.003).
CONCLUSIONS
Shisha smoking was associated with an increased risk of developing cardiovascular disease. However, this association did not reach the level of statistical significance within this study. A finding to consider that showed strong evidence is the younger age of initial shisha smoking in cases. Further studies are needed to demonstrate the true relationship between shisha smoking and cardiovascular disease.
Keywords: cardiovascular diseases risk, heart attack, shisha, waterpipe, hookah
INTRODUCTION
Cardiovascular diseases (CVDs) are the major cause of death worldwide. In 2019, an estimated 17.9 million individuals died from CVDs, accounting for 32% of all global deaths1. Eighty-five per cent of these deaths were caused by a heart attack or a stroke1. More than three-quarters of CVD deaths occur in low- and middle-income nations1. According to Qatar’s planning and statistical authorities, angina and stroke were among the leading causes of mortality in 2017, accounting for 32% of the deaths in Qatar2. The inter-heart study of myocardial infarction cases in 52 countries, identified nine modifiable factors that account for myocardial infarction in both genders3. These factors include smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, fruit, vegetable, and alcohol consumption, and regular physical activity3-6.
Tobacco smoking is a preventable cause of disease and mortality worldwide7. Shisha has become lately a popular method of smoking tobacco7. Shisha is sometimes referred to as waterpipe, hookah, and narghile. The global percentage of shisha smokers is continuously increasing7. Eastern Mediterranean and European nations have the highest rates of shisha smoking, which appears to be more common among teenagers than adults8. In Qatar, many individuals smoke cigarettes or traditional hookahs9. A study done in 2019 showed that 25.2% (n=6904) of a sample in Qatar smoke tobacco10; of the 6904, 8.3% (n=570) were shisha smokers11.
Shisha smoking has a harmful effect on the body and cardiovascular system12. Shisha, like cigarettes, burns tobacco which produces toxic compounds including nitrosamine and polycyclic aromatic hydrocarbons, which are both carcinogens and increase the risk of developing CVD13,14. Oxidative stress is believed to be a major contributor to the pathophysiology of shisha smoking, which is associated with an increased risk of CVD and death with long-term use14. It has been shown that there is a positive association between shisha smoking and cancer risk, specifically lung and esophageal cancers15. Additionally, shisha smoking regularly is associated with respiratory complications, including reduced pulmonary functions and increased risk for COPD16. Many studies have found that shisha smokers’ systolic and diastolic blood pressure and heart rate increase after smoking17. In contrast to cigarette smoking, less is known regarding the health consequences of shisha use7. This study aims to assess the association between shisha smoking and CVD among the population of Qatar Biobank (QBB). This study is important as the association between shisha smoking and CVD has not been studied thoroughly, and hence, it is perceived in the population that shisha smoking is less harmful compared to cigarette smoking18.
METHODS
Study design and settings
The design of this study is analytical cross-sectional. Data were collected from QBB (https://www.qatarbiobank.org.qa/), which is a program that was started in December 2012 to collect biological samples and data on the health and lifestyle of a portion of Qatar’s population. Participants from QBB are aged ≥18 years and are either Qataris or long-term residents of Qatar (at least 15 years)19. Information obtained from QBB included demographics (age, gender, nationality, BMI, etc.), medical history (hypertension, diabetes, medications, etc.), laboratory measurements (cholesterol, LDL, glucose, insulin, etc.), and smoking status (shisha smoker, cigarette smoker, previous smoker, never smoker) for all participants.
Definition of cases and controls
The study population consisted of 1045 individuals from the QBB cohort who had reported diagnoses of CVD and their matched healthy controls. The measurement of both the exposure and the outcome was done through the survey provided by QBB. A case was defined as a participant who reported a history of heart attack, angina and/or stroke diagnosis. This was done through QBB’s survey which asked the question: ‘Has a doctor ever told you that you have or had any of the following conditions?’. Inclusion criterion was those who met the case definition. Those who did not meet QBB’s eligibility criteria were excluded. A control was defined as a patient who did not report a history of heart attack, angina and/or stroke. QBB had a total of 209 participants with CVD in their database, and all of them were included in our study. Each case was matched to four controls for age and gender randomly (1:4). The total study population was 1045 after matching for age (±1 year) and gender. For instance, a male patient aged 45 years who reported a history of CVD diagnosis was matched with 4 male controls who were aged 44–46 years. This was done to increase the power of the study.
Smoking status
Smoking history was determined from the survey. The survey asked: ‘Do you currently smoke?’. Participants were then categorized as current or former smokers, accordingly. The survey also asked questions such as ‘what do/did you usually smoke?’ and participants were categorized as cigarette or shisha smokers, accordingly. Participants who only smoked shisha were categorized as exclusive shisha smokers. Participants who only smoked cigarettes were categorized as exclusive cigarette smokers. Participants who smoked both cigarettes and shisha were categorized as dual shisha and cigarette smokers. The initial age of shisha smoking was also determined from the survey, which asked the question: ‘How old were you when you first started smoking waterpipe (shisha)?’.
Other variables
Sedentary lifestyle was determined if the participants’ level of activity in their main occupations involved them sitting most of the time. Participants were considered obese if their BMI was ≥30 kg/m2. Abdominal obesity was defined as a waist-to-hip ratio >0.85 for females and >0.9 for males. Low income was defined as a monthly salary of ≤20000 QAR (100 Qatari Riyals about US$27). Medical diagnoses and medications were self-reported by participants. For example, a participant was considered to have history of diabetes diagnosis if he/she answered ‘Yes’ to the question: ‘Has a doctor ever told you that you had or have diabetes?’. Laboratory biochemical values, such as total cholesterol, were measured by QBB at the time of enrollment of volunteers. Monocyte to HDL ratio was calculated by dividing monocyte percentage by HDL cholesterol levels20. HOMA2 IR levels were calculated using University of Oxford’s HOMA calculator. Participants were considered to be fasting if their fasting time was ≥8 hours. Missing data in the study range from 14 to 125 participants. Smoking history had 94 missing responses, of which 76 were controls (9.1%) and 19 were cases (8.6%).
Statistical analysis
Mean and standard deviation were used to express normally distributed continuous variables, and median and interquartile range (IQR) were used to express continuous variables that are not normally distributed. Frequency and percentage were used to express categorical variables.
The chi-squared test was used to compare categorical variables between cases and their matched controls. The independent t-test was used to compare the means of normally distributed continuous variables, and the Wilcoxon rank-sum test was used to compare the medians of continuous variables that are not normally distributed. A conditional logistic regression model was used to assess the association between smoking and CVD after adjusting for covariates. Confounding variables were determined after conducting a literature review on the variables of interest and creating a corresponding Directed Acyclic Graph (DAG). Stata 17 was used to carry out all the statistical analyses, and exact p-values are reported.
Ethics statement
The study was approved by QBB’s Institutional Review Board and researchers signed a non-disclosure agreement to maintain confidentiality before receiving the data from QBB.
RESULTS
A total of 1045 participants were divided into two groups, controls (n=836) and cases (n=209), matched for age and gender. Table 1 shows the baseline characteristics of both groups including demographics, medical history, and smoking history. The average age of both groups was 55.6 years. There were no differences in height, weight, obesity, abdominal obesity and education level between the two groups. There was no difference in the systolic blood pressure (mmHg), while the diastolic blood pressure showed a difference with a mean of 70.4 mmHg in the control group compared with a mean of 68.6 in the cases (p=0.031). More cases reported sedentary lifestyle compared to controls (p=0.002). There was a difference in monthly income between the two groups, as cases had a higher proportion of people with low income (p=0.032). Cases were more likely to have diabetes, hypertension and dyslipidemia (p<0.001) and they were also more likely to be treated for these conditions (p<0.001).
Table 1.
Baseline characteristics of cases with heart attack, angina, and/or stroke and matched controls for age and gender, Qatar, 2022 (N=1045)
| Characteristics | Controls (n=836) n (%) | Cases (n=209) n (%) | p |
|---|---|---|---|
| Demographics | |||
| Age (years), mean ± SD | 55.6 ± 12.0 | 55.6 ± 12.0 | 1.00a |
| Gender (male) | 552 (66.0) | 138 (66.0) | 1.00b |
| Nationality (Qatari) | 666 (79.7) | 163 (78.0) | 0.59b |
| Height (cm), mean ± SD | 181.9 ± 88.8 | 175.7 ± 85.6 | 0.36a |
| Weight (kg), mean ± SD | 83.5 ± 16.0 | 83.4 ± 16.3 | 0.89a |
| Obesity* | 411 (49.7) | 107 (51.7) | 0.61b |
| Abdominal obesity* | 526 (63.8) | 143 (69.1) | 0.16b |
| SDP (mmHg), mean ± SD | 125.5 ± 17.1 | 126.4 ± 17.2 | 0.51a |
| DPB (mmHg), mean ± SD | 70.4 ± 10.7 | 68.6 ± 11.5 | 0.031a |
| Sedentary lifestyle* | 322 (41.7) | 107 (54.0) | 0.002b |
| Education level (university or higher)* | 414 (50.5) | 89 (54.0) | 0.052b |
| Low income* | 354 (48.5) | 109 (57.4) | 0.029b |
| Medical history | |||
| Diabetes diagnosis | 361 (43.2) | 132 (63.2) | <0.001b |
| Hypertension diagnosis* | 259 (31.9) | 104 (50.2) | <0.001b |
| Dyslipidemia diagnosis | 403 (48.2) | 143 (68.4) | <0.001b |
| Diabetes medication | 260 (31.1) | 109 (52.2) | <0.001b |
| Hypertension medication | 213 (25.5) | 91 (43.5) | <0.001b |
| Dyslipidemia medication | 251 (30.0) | 99 (47.4) | <0.001b |
| Smoking history | |||
| Current smokers* | 143 (18.8) | 35 (18.3) | 0.88b |
| Former smokers* | 141 (18.6) | 48 (25.1) | 0.042b |
| Smoking type | |||
| Exclusive shisha smokers* | 53 (7.0) | 13 (6.8) | 0.94b |
| Exclusive cigarette smokers* | 88 (11.6) | 28 (14.7) | 0.24b |
| Dual shisha and cigarette smokers* | 143 (18.8) | 42 (22.0) | 0.32b |
SDP: systolic blood pressure. DPB: diastolic blood pressure. IQR: interquartile range. SD: standard deviation.
Independent t-test.
Chi-squared.
Wilcoxon rank-sum.
Missing participant responses range from 14 to 125.
In this study, smoking history was positive in 284 of the participants. Current smokers accounted for 18.3% of the cases and 18.8% of the controls (p=0.88). The percentage of former smokers was higher in cases compared to controls (25.1% vs 18.6%, p=0.042). Exclusive shisha smokers constituted 6.8% of the cases and 7% of the controls (p=0.94). Exclusive cigarette smokers made up 14.7% of the cases and 11.6% of the controls (p=0.24); 22% of cases and 18.8% of controls were dual shisha and cigarette smokers (p=0.32). The median age of initial shisha smoking (Figure 1) was lower in cases compared to controls (20 years vs 25 years, p=0.003).
Figure 1.
Box plot of initial shisha smoking age by heart attack, angina, and/or stroke history (p=0.003), Qatar, 2022
Table 2 depicts the measured laboratory biochemical values of cases and controls. The data revealed that cases have higher levels of HbA1c compared to controls (p<0.001). The cases showed better lipid profile compared with controls. The mean of total cholesterol is lower among cases with CVD compared to controls (4.7 vs 5.0 mmol/L, p=0.003). LDL cholesterol levels were lower in cases compared with controls (2.7 vs 3.0 mmol/L, p=0.002). HDL cholesterol levels are different between cases and controls (p=0.042) with means of 1.2 and 1.3 mmol/L, respectively. For renal function tests, serum creatinine was higher in the cases with a median of 74.0 µmol/L, while the control group had a median of 72.0 µmol/L (p=0.019). The mean of urea was 5.8 mmol/L in the cases compared with 4.9 mmol/L in the controls (p<0.001). The levels of homocysteine differ between the cases and controls with medians of 11.0 and 10.0 µmol/L, respectively (p=0.034).
Table 2.
Selected laboratory variables for cases with heart attack, angina, and/or stroke and matched controls for age and gender, Qatar, 2022 (N=1045)
| Variables | Controls (n=836) Mean ± SD or Median (IQR) | Cases (n=209) Mean ± SD or Median (IQR) | p |
|---|---|---|---|
| Fasting glucose (mmol/L) | 5.6 (5.0–7.4) | 6.1 (5.2–7.8) | 0.018c |
| Fasting C-Peptide (ng/mL) | 2.4 ± 1.1 | 2.5 ± 1.5 | 0.48a |
| Fasting insulin (µU/mL) | 11.2 (7.7–16.9) | 11.0 (8.0–16.1) | 0.85c |
| HbA1c (%) | 5.8 (5.4–6.9) | 6.5 (5.6–8.2) | <0.001c |
| Total cholesterol (mmol/L) | 5.0 ± 1.1 | 4.7 ± 1.1 | 0.003a |
| HDL cholesterol (mmol/L) | 1.3 ± 0.4 | 1.2 ± 0.4 | 0.042a |
| LDL cholesterol (mmol/L) | 3.0 ± 1.0 | 2.7 ± 1.1 | 0.002a |
| Triglyceride (mmol/L) | 1.3 (1.0–1.8) | 1.5 (1.0–2.1) | 0.026a |
| Creatinine (µmol/L) | 72.0 (61.0–82.0) | 74.0 (63.0–87.0) | 0.019c |
| Monocyte to HDL ratio | 6.6 ± 2.6 | 6.7 ± 2.4 | 0.60c |
| Urea (mmol/L) | 4.9 ± 1.6 | 5.8 ± 3.6 | <0.001a |
| Ferritin (µg/L) | 78.2 (34.0–140.5) | 69.0 (28.2–122.0) | 0.086a |
| Homocysteine (µmol/L) | 10.0 (8.0–12.5) | 11.0 (8.4–13.0) | 0.034c |
| Total dihydroxyvitamin D (ng/mL) | 20.0 (14.0–28.0) | 21.0 (15.0–29.0) | 0.23c |
| HOMA2 IR | 5.67 ± 2.67 | 6.06 ± 3.36 | 0.17c |
HDL: high-density lipoprotein. LDL: low-density lipoprotein.
Independent t-test.
Chi-squared.
Wilcoxon rank-sum.
IQR: interquartile range. SD: standard deviation.
Table 3 shows the conditional logistic regression model (matched for age and gender) analysis of the smoking effect, including exclusive shisha, exclusive cigarette, and dual shisha and cigarette smoking, on CVD diagnosis. After adjusting for covariates, including hypertension, diabetes, dyslipidemia, abdominal obesity, and sedentary lifestyle, exclusive shisha smokers had 65% higher odds of reporting cardiovascular disease diagnoses compared to non-smokers (95% CI: 0.78–3.48). Exclusive cigarette smokers had 39% higher odds of reporting cardiovascular disease diagnoses compared to non-smokers (95% CI: 0.79–2.43). Those who smoked both shisha and cigarettes had 47% higher odds of reporting cardiovascular disease diagnoses compared to non-smokers (95% CI: 0.88–2.45). However, these findings were not statistically significant at the given sample size. An analysis was conducted to explore the association between smoking and stroke and coronary artery disease separately (Supplementary file Tables S1 and S2).
Table 3.
Association between smoking history and history of heart attack, stroke, and/or angina by multivariable conditional logistic regression, Qatar, 2022 (N=824)
| Variable | OR (95% CI) | p | AOR (95% CI) | p |
|---|---|---|---|---|
| Exclusive shisha smokers | 1.25 (0.63–2.49) | 0.52 | 1.65 (0.78–3.48) | 0.19 |
| Exclusive cigarette smokers | 1.55 (0.92–2.62) | 0.10 | 1.39 (0.79–2.43) | 0.25 |
| Dual shisha and cigarette smokers | 1.44 (0.90–2.30) | 0.13 | 1.47 (0.88–2.45) | 0.14 |
AOR: adjusted odds ratio; adjusted for hypertension diagnosis, diabetes diagnosis, dyslipidemia diagnosis, abdominal obesity, and sedentary lifestyle. In all, 84 participants were omitted because of all positive or all negative outcomes.
DISCUSSION
This study focused on smoking, particularly shisha smoking, and the risk of developing CVD in adults residing in Qatar. This was done by analyzing the odds of CVD diagnosis after adjusting for covariates (hypertension, diabetes, dyslipidemia, sedentary lifestyle, and abdominal obesity). We found that exclusive shisha smokers had higher odds of reporting CVD diagnoses compared to non-smokers. However, there was little evidence against the null hypothesis at the given sample size. This may be attributed to the small sample size in which there was a very limited number of exclusive shisha smokers in the study (n=66), which potentially led to random error.
It was noted in the results that cases had a younger age of initial shisha smoking. This is probably because younger starting age will lead to a longer duration of exposure. However, the duration of shisha smoking was not assessed in this study because a large number of participants had missing information in this aspect. From a preventative perspective, doctors may consider paying more attention to raising younger adults’ awareness, which may help to reduce the duration of exposure.
No studies were conducted exclusively in Qatar on the association between CVD and shisha smoking. One study reported the prevalence of shisha and cigarette smoking in Qatar11. A recent study conducted in both Qatar and Lebanon showed that shisha smoking was associated with the presence of coronary artery calcium (CAC), which is a marker of coronary artery disease21. Another study showed that exclusive waterpipe smoking was linked to increased arterial stiffness in a community-based sample, which is a predictor of cardiovascular disease22. Several studies in the Middle East and South-East Asia have found an association between long-term waterpipe use and increased CVD risk, severity, and mortality23-25. Nonetheless, the majority of these studies have various limitations26. A study conducted in Saudi Arabia showed a significant association between shisha smoking and myocardial infarction27. However, the study conducted was not generalizable given its small sample size; in addition to having a low internal validity given the fact that the patients self-reported their diagnoses.
Those participants with a prior diagnosis of CVD had lower total cholesterol and LDL cholesterol levels compared to controls. This may be attributed to the fact that a larger proportion of the cases have a diagnosis of dyslipidemia, and are thus taking lipid-lowering agents. Furthermore, these patients were most likely prescribed statins as they are indicated for CVD patients28. This is consistent with the results of a prior study that showed that patients with myocardial infarction or angina had improved lipid profiles and a lower prevalence of dyslipidemia one year after percutaneous coronary intervention (PCI)29.
Strengths and limitations
One of the major strengths of this study is that cases and controls were matched for age and gender, which are both confounders. In addition, we adjusted for other covariates, including hypertension, diabetes, dyslipidemia, abdominal obesity, and sedentary lifestyle to eliminate the possibility that the variation in results between the two groups is due to differences in these variables. Another strength is that this is the first study conducted exclusively in Qatar that has ever been done to assess the effect of shisha smoking on the development of CVDs.
The study had some limitations. Among the cases (n=209), there were few exclusive shisha smokers (n=13) as most shisha smokers were cigarette smokers too. In addition, because of the nature of data collection and study design, a causal association could not be assessed. Moreover, QBB’s population is not representative of the general population of Qatar, which may limit the generalizability of our study.
There are some limitations regarding the outcome definition, as it is self-reported with no specific diagnostic criteria and missing data on the time of diagnosis. This study also did not assess other forms of tobacco smoking such as cigars. The frequency of exposure to shisha smoking was also not assessed, which warrants further investigations. To evaluate the association between CVD and shisha smoking and reduce the chance of error, more studies with larger sample sizes and proper designs are needed. For example, a prospective study or a study where directionality can be assessed.
CONCLUSIONS
This was the first study conducted exclusively in Qatar to investigate the association between shisha smoking and the development of CVD. Shisha smoking is associated with increased risk of developing CVD. However, this association did not reach the level of statistical significance within the study. A key finding in this study is that the younger age to start shisha smoking is significantly associated with increased risk of CVD. Finally, studies with appropriate sample size, design, and measurement of exposure and outcome are required to demonstrate a true relationship between shisha smoking and CVD.
Supplementary Material
ACKNOWLEDGEMENTS
The authors thank Qatar Biobank (https://www.qatarbiobank.org.qa/) for providing the dataset used in this study. The authors also thank Suhail Doi, Giridhara Babu, and Tawanda Chivese of the Population Medicine Department, College of Medicine, Qatar University, for their continuous assistance in conducting the research.
CONFLICTS OF INTEREST
The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.
FUNDING
The publication of this article was made possible due to a generous fund from QU Health, Qatar University.
ETHICAL APPROVAL AND INFORMED CONSENT
Ethical approval was obtained from the Qatar Biobank’s Institutional Review Board (Approval number: Ex-2022-QF-QBB-RES-ACC-00070-0189; Date: March 2022). Additionally, researchers signed a non-disclosure agreement to maintain confidentiality before receiving the data from Qatar Biobank. Participation in the survey was deemed informed consent.
DATA AVAILABILITY
The data supporting this research cannot be made available for privacy or other reasons. The cohort data used in this current study were obtained from Qatar Biobank repository in Doha, Qatar [https://www.qatarbiobank.org.qa/] under a Material Transfer agreement, and thus are not publicly available. Upon reasonable request, S. Zughaier (szughaier@qu.edu.qa) will facilitate communication with the Qatar Biobank.
AUTHORS’ CONTRIBUTIONS
Conceptualization: EM and AE. Visualization: EM. Methodology: EM, AE and HHF. Investigation: EM, AE and YE. Formal analysis: EM, AE, YE and HHF. Data curation: EM, AE, YE and HHF. Resources: AA and SMZ. Writing of original draft: EM, AE, YE, AA, FM, NAQ and WAM. Writing, reviewing and editing: EM, YE, AA, NAQ, HHF and SMZ. Supervision: HHF and SMZ. Project administration: SMZ and AA.
PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.
REFERENCES
- 1.World Health Organization . Cardiovascular diseases (CVDs) World Health Organization; 2021. Accessed August 30, 2022. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)/ [Google Scholar]
- 2.Planning and Statistics Authority . Births & Deaths: In the State of Qatar. Planning and Statistics Authority; 2018. Accessed November 7, 2022. https://www.psa.gov.qa/en/statistics/Statistical%20Releases/Population/BirthsDeaths/2017/Birth_death_2017_EN.pdf . [Google Scholar]
- 3.Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9. [DOI] [PubMed] [Google Scholar]
- 4.Boehme AK, Esenwa C, Elkind MS. Stroke Risk Factors, Genetics, and Prevention. Circ Res. 2017;120(3):472–495. doi: 10.1161/CIRCRESAHA.116.308398. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Tadi P, Lui F. StatPearls. StatPearls Publishing; 2022. Acute Stroke. Accessed September 28, 2022. https://www.ncbi.nlm.nih.gov/books/NBK535369/ [PubMed] [Google Scholar]
- 6.Wilson PWF. Overview of established risk factors for cardiovascular disease. Updated January 11, 2023. Accessed February 7, 2023. https://www.uptodate.com/contents/overview-of-established-risk-factors-for-cardiovascular-disease?search=Overview%20of%20established%20risk%20factors%20for%20cardiovascular%20disease&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
- 7.Aslam HM, Saleem S, German S, Qureshi WA. Harmful effects of shisha: literature review. Int Arch Med. 2014;7:16. doi: 10.1186/1755-7682-7-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Jawad M, Charide R, Waziry R, Darzi A, Ballout RA, Akl EA. The prevalence and trends of waterpipe tobacco smoking: A systematic review. PLoS One. 2018;13(2):e0192191. doi: 10.1371/journal.pone.0192191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Qatar Ministry of Public Health Tobacco Control. Accessed July 3, 2022. https://www.moph.gov.qa/english/strategies/Supporting-Strategies-and-Frameworks/QatarPublicHealthStrategy/Pages/Tobacco-control.aspx.
- 10.AlMulla A, Mamtani R, Cheema S, et al. Epidemiology of tobacco use in Qatar: Prevalence and its associated factors. PLoS One. 2021;16(4):e0250065. doi: 10.1371/journal.pone.0250065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.AlMulla A, Kouyoumjian S, Maisonneuve P, Cheema S, Mamtani R. Waterpipe smoking: Results from a population-based study in Qatar. Tob Induc Dis. 2022;20(June) doi: 10.18332/tid/149907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Waziry R, Jawad M, Ballout RA, Al Akel M, Akl EA. The effects of waterpipe tobacco smoking on health outcomes: an updated systematic review and meta-analysis. Int J Epidemiol. 2017;46(1):32–43. doi: 10.1093/ije/dyw021. [DOI] [PubMed] [Google Scholar]
- 13.Münzel T, Hahad O, Kuntic M, Keaney JF, Deanfield JE, Daiber A. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. Eur Heart J. 2020;41(41):4057–4070. doi: 10.1093/eurheartj/ehaa460. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Badran M, Laher I. Waterpipe (shisha, hookah) smoking, oxidative stress and hidden disease potential. Redox Biol. 2020;34:101455. doi: 10.1016/j.redox.2020.101455. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Montazeri Z, Nyiraneza C, El-Katerji H, Little J. Waterpipe smoking and cancer: systematic review and meta-analysis. Tob Control. 2017;26(1):92–97. doi: 10.1136/tobaccocontrol-2015-052758. [DOI] [PubMed] [Google Scholar]
- 16.Darawshy F, Abu Rmeileh A, Kuint R, Berkman N. Waterpipe smoking: a review of pulmonary and health effects. Eur Respir Rev. 2021;30(160):200374. doi: 10.1183/16000617.0374-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kadhum M, Jaffery A, Haq A, Bacon J, Madden B. Measuring the acute cardiovascular effects of shisha smoking: a cross-sectional study. JRSM Open. 2014;5(6):2054270414531127. doi: 10.1177/2054270414531127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Jaam M, Al-Marridi W, Fares H, Izham M, Kheir N, Awaisu A. Perception and intentions to quit among waterpipe smokers in Qatar: a cross-sectional survey. Public Health Action. 2016;6(1):38–43. doi: 10.5588/pha.15.0054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Al Thani A, Fthenou E, Paparrodopoulos S, et al. Qatar Biobank Cohort Study: Study Design and First Results. Am J Epidemiol. 2019;188(8):1420–1433. doi: 10.1093/aje/kwz084. [DOI] [PubMed] [Google Scholar]
- 20.Mousa H, Islam N, Ganji V, Zughaier SM. Serum 25-Hydroxyvitamin D Is Inversely Associated with Monocyte Percentage to HDL Cholesterol Ratio among Young Healthy Adults in Qatar. Nutrients. 2020;13(1):127. doi: 10.3390/nu13010127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Chami HA, Isma’eel H, Tamim H, Adawi M, Al Kuwari M, Al Mullah A. The Association of Water-Pipe Smoking and Coronary Artery Calcium in a CommunityBased Sample. Chest. 2019;155(6):1217–1225. doi: 10.1016/j.chest.2019.01.010. [DOI] [PubMed] [Google Scholar]
- 22.Chami HA, Isma’eel H, Mitchel GF, et al. The association of waterpipe smoking with arterial stiffness and wave reflection in a community-based sample. Blood Press. 2021;30(5):300–309. doi: 10.1080/08037051.2021.1947778. [DOI] [PubMed] [Google Scholar]
- 23.Cobb CO, Sahmarani K, Eissenberg T, Shihadeh A. Acute toxicant exposure and cardiac autonomic dysfunction from smoking a single narghile waterpipe with tobacco and with a “healthy” tobacco-free alternative. Toxicol Lett. 2012;215(1):70–75. doi: 10.1016/j.toxlet.2012.09.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Nelson MD, Rezk-Hanna M, Rader F, et al. Acute Effect of Hookah Smoking on the Human Coronary Microcirculation. Am J Cardiol. 2016;117(11):1747–1754. doi: 10.1016/j.amjcard.2016.03.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Blank MD, Cobb CO, Kilgalen B, et al. Acute effects of waterpipe tobacco smoking: a double-blind, placebo-control study. Drug Alcohol Depend. 2011;116(1-3):102–109. doi: 10.1016/j.drugalcdep.2010.11.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Bhatnagar A, Maziak W, Eissenberg T, et al. Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association. Circulation. 2019;139(19):e917–e936. doi: 10.1161/CIR.0000000000000671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Al-Amri A, Ghalilah K, Al-Harbi A, Al-Dubai SAR, Al-Ghamdi S, Al-Zalabani A. Waterpipe smoking and the risk of myocardial infarction: A hospital-based case-control study. Tob Induc Dis. 2019;17(December) doi: 10.18332/tid/114074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Hennekens CH, Lopez-Sendon J. Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk. UpToDate; 2022. Accessed July 3, 2022. https://www.uptodate.com/contents/prevention-of-cardiovascular-disease-events-in-those-with-established-disease-secondary-prevention-or-at-very-high-risk. [Google Scholar]
- 29.Qiu W, Chen J, Huang X, Guo J. The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study. Lipids Health Dis. 2020;19(1):163. doi: 10.1186/s12944-020-01340-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data supporting this research cannot be made available for privacy or other reasons. The cohort data used in this current study were obtained from Qatar Biobank repository in Doha, Qatar [https://www.qatarbiobank.org.qa/] under a Material Transfer agreement, and thus are not publicly available. Upon reasonable request, S. Zughaier (szughaier@qu.edu.qa) will facilitate communication with the Qatar Biobank.